{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T07:14:06Z","timestamp":1789110846529,"version":"build-2803163510"},"reference-count":27,"publisher":"Becaris Publishing Limited","issue":"10","funder":[{"DOI":"10.13039\/100007013","name":"F Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            To determine if emicizumab was channeled to clinically complex people with hemophilia A upon approval.\n            <jats:bold>Methods:<\/jats:bold>\n            Claims data (16\u00a0November\u00a02017, through 31\u00a0December\u00a02019) from US-based insurance databases were analyzed to compare the clinical complexity of people with hemophilia A initiating emicizumab with matched individuals receiving factor VIII (FVIII) episodically or prophylactically. People with hemophilia A with evidence of previous bypassing agent use (indicating FVIII inhibitors) were excluded. Outcomes included bleeding events, arthropathy, pain, comorbidities and healthcare costs.\n            <jats:bold>Results:<\/jats:bold>\n            A larger proportion of emicizumab users had bleeding events, comorbidities and arthropathy and greater healthcare costs in the year prior to starting emicizumab compared with FVIII users.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Claims-based data limitations prevent an absolute conclusion. Nevertheless, emicizumab users appear more clinically complex than FVIII users, suggesting post-approval channeling.\n          <\/jats:p>","DOI":"10.2217\/cer-2021-0278","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T10:02:07Z","timestamp":1652176927000},"page":"717-728","source":"Crossref","is-referenced-by-count":6,"title":["Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A"],"prefix":"10.57264","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0549-0155","authenticated-orcid":false,"given":"Arash","family":"Mahajerin","sequence":"first","affiliation":[{"name":"Divisions of Pediatric Hematology and Oncology, University of California, Irvine and CHOC Children's Specialists, Irvine, CA 92868, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imi","family":"Faghmous","sequence":"additional","affiliation":[{"name":"Department of Real-World Data Oncology-Hematology, F Hoffmann-La Roche Ltd., Basel, CH-4070, Switzerland"},{"name":"Current affiliation: Faculty of Health, Medicine and Life Sciences, University of Maastricht, Maastricht, P Debyeplein15, DEB15, 6229 HA, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kuebler","sequence":"additional","affiliation":[{"name":"Department of Personalized Healthcare Safety Interface, Genentech, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monet","family":"Howard","sequence":"additional","affiliation":[{"name":"Department of Clinical Safety, F Hoffmann-La Roche Ltd., Mississauga, ON, L5N 5M8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Personalized Healthcare Product Development, F Hoffmann-La Roche Ltd., Basel, CH-4070, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-4258","authenticated-orcid":false,"given":"Carlos","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Evidence Strategy, Genesis Research, Hoboken, NJ 07030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Personalized Healthcare Safety Interface, Genentech, Inc., South San Francisco, CA 94080, USA"},{"name":"Current affiliation: Department of Hematology, Spark Therapeutics, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-0982","authenticated-orcid":false,"given":"Francis","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Real-World Data Oncology-Hematology, F Hoffmann-La Roche Ltd., Basel, CH-4070, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"4","key":"e_1_3_6_3_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/sim.4780100409","article-title":"Channeling bias in the interpretation of drug effects","volume":"10","author":"Petri H","year":"1991","unstructured":"Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat. Med. 10(4), 577\u2013581 (1991).","journal-title":"Stat. Med."},{"issue":"6","key":"e_1_3_6_4_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/acr.20124","article-title":"Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis","volume":"62","author":"Hudson M","year":"2010","unstructured":"Hudson M, Suissa S. Avoiding common pitfalls in the analysis of observational studies of new treatments for rheumatoid arthritis. Arthritis Care Res. 62(6), 805\u2013810 (2010).","journal-title":"Arthritis Care Res."},{"key":"e_1_3_6_5_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of hemophilia: a narrative review","volume":"7","author":"Franchini M","year":"2012","unstructured":"Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J. Rare Dis. 7, 24 (2012).","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"e_1_3_6_6_2","first-page":"178","article-title":"The modern treatment of haemophilia: a narrative review","volume":"11","author":"Franchini M","year":"2013","unstructured":"Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus. 11(2), 178\u2013182 (2013).","journal-title":"Blood Transfus."},{"issue":"6","key":"e_1_3_6_7_2","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort L","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 17(6), 479\u2013486 (2019).","journal-title":"Blood Transfus."},{"issue":"21","key":"e_1_3_6_8_2","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII \u2013 mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima M","year":"2016","unstructured":"Shima M, Hanabusa H, Taki M Factor VIII \u2013 mimetic function of humanized bispecific antibody in hemophilia A. N. Engl. J. Med. 374(21), 2044\u20132053 (2016).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_6_9_2","unstructured":"US FDA. FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors (2017). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-emicizumab-kxwh-prevention-and-reduction-bleeding-patients-hemophilia-factor-viii"},{"key":"e_1_3_6_10_2","unstructured":"FDA. FDA approves emicizumab-kxwh for hemophilia A with or without factor VIII inhibitors (2018). www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-emicizumab-kxwh-hemophilia-or-without-factor-viii-inhibitors"},{"issue":"9","key":"e_1_3_6_11_2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg J","year":"2017","unstructured":"Oldenburg J, Mahlangu JN, Kim B Emicizumab prophylaxis in hemophilia A with inhibitors. N. Engl. J. Med. 377(9), 809\u2013818 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_6_12_2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu J","year":"2018","unstructured":"Mahlangu J, Oldenburg J, Paz-Priel I Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N. Engl. J. Med. 379(9), 811\u2013822 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_6_13_2","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe SW","year":"2019","unstructured":"Pipe SW, Shima M, Lehle M Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 6(6), e295\u2013e305 (2019).","journal-title":"Lancet Haematol."},{"issue":"24","key":"e_1_3_6_14_2","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young G","year":"2019","unstructured":"Young G, Liesner R, Chang T A multicenter, open-label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134(24), 2127\u20132138 (2019).","journal-title":"Blood"},{"issue":"2","key":"e_1_3_6_15_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.16964","article-title":"Emicizumab treatment and monitoring in a paediatric cohort: real-world data","volume":"191","author":"Barg AA","year":"2020","unstructured":"Barg AA, Livnat T, Budnik I Emicizumab treatment and monitoring in a paediatric cohort: real-world data. Br. J. Haematol. 191(2), 282\u2013290 (2020).","journal-title":"Br. J. Haematol."},{"key":"e_1_3_6_16_2","article-title":"Second interim analysis results from the STASEY trial: a single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors","author":"Jimenez-Yuste V","year":"2020","unstructured":"Jimenez-Yuste V, Klamroth R, Castaman G Second interim analysis results from the STASEY trial: a single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors. ISTH (2020). (PosterPB0958).","journal-title":"ISTH"},{"issue":"4","key":"e_1_3_6_17_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/hae.14005","article-title":"Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures","volume":"26","author":"McCary I","year":"2020","unstructured":"McCary I, Guelcher C, Kuhn J Real-world use of emicizumab in patients with haemophilia A: bleeding outcomes and surgical procedures. Haemophilia 26(4), 631\u2013636 (2020).","journal-title":"Haemophilia"},{"issue":"12","key":"e_1_3_6_18_2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1080\/03007995.2019.1649378","article-title":"Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial","volume":"35","author":"Reyes A","year":"2019","unstructured":"Reyes A, R\u00e9vil C, Niggli M Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr. Med. Res. Opin. 35(12), 2079\u20132087 (2019).","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"e_1_3_6_19_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer C","year":"2013","unstructured":"Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther. Adv. Hematol. 4(1), 59\u201372 (2013).","journal-title":"Ther. Adv. Hematol."},{"issue":"4","key":"e_1_3_6_20_2","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1111\/hae.13220","article-title":"Real-world resource use and costs of haemophilia A-related bleeding","volume":"23","author":"Shrestha A","year":"2017","unstructured":"Shrestha A, Eldar-Lissai A, Hou N, Lakdawalla DN, Batt K. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia 23(4), e267\u2013e275 (2017).","journal-title":"Haemophilia"},{"issue":"6","key":"e_1_3_6_21_2","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1111\/hae.14421","article-title":"Patient preference for emicizumab versus prior factor therapy in persons with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies","volume":"27","author":"Parnes A","year":"2021","unstructured":"Parnes A, Mahlangu JN, Pipe SW Patient preference for emicizumab versus prior factor therapy in persons with haemophilia A: results from the HAVEN 3 and HAVEN 4 studies. Haemophilia 27(6), e772\u2013e775 (2021).","journal-title":"Haemophilia"},{"issue":"1","key":"e_1_3_6_22_2","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2019-122300","article-title":"Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with severe hemophilia A without inhibitors: results from the phase 2 explorer5 trial","volume":"134","author":"Eichler H","year":"2019","unstructured":"Eichler H, Angchaisuksiri P, Astermark J Efficacy and safety of subcutaneous prophylaxis with concizumab in patients with severe hemophilia A without inhibitors: results from the phase 2 explorer5 trial. Blood 134(Suppl. 1), 2417 (2019).","journal-title":"Blood"},{"key":"e_1_3_6_23_2","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia A or B with and without inhibitors","author":"Pasi KJ","year":"2017","unstructured":"Pasi KJ, Georgiev P, Mant T Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: interim results from a phase 2 extension study in patients with hemophilia A or B with and without inhibitors. ISTH. OC 11.13 (2017).","journal-title":"ISTH"},{"issue":"1","key":"e_1_3_6_24_2","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1093\/hmg\/ddz157","article-title":"Advances and challenges for hemophilia gene therapy","volume":"28","author":"Batty P","year":"2019","unstructured":"Batty P, Lillicrap D. Advances and challenges for hemophilia gene therapy. Hum. Mol. Genet. 28(R1), R95\u2013R101 (2019).","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"e_1_3_6_25_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/asheducation-2015.1.41","article-title":"Managing older patients with hemophilia","volume":"2015","author":"Angelini D","year":"2015","unstructured":"Angelini D, Sood SL. Managing older patients with hemophilia. Hematology 2015(1), 41\u201347 (2015).","journal-title":"Hematology"},{"issue":"5","key":"e_1_3_6_26_2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1538-7836.2009.03318.x","article-title":"Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy","volume":"7","author":"Siboni SM","year":"2009","unstructured":"Siboni SM, Mannucci PM, Gringeri A Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J. Thromb. Haemost. 7(5), 780\u2013786 (2009).","journal-title":"J. Thromb. Haemost."},{"key":"e_1_3_6_27_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JBM.S43734","article-title":"Barriers and perceived limitations to early treatment of hemophilia","volume":"4","author":"Saxena K","year":"2013","unstructured":"Saxena K. Barriers and perceived limitations to early treatment of hemophilia. J. Blood Med. 4, 49\u201356 (2013).","journal-title":"J. Blood Med."},{"issue":"1","key":"e_1_3_6_28_2","first-page":"32","article-title":"Application of a hemophilia mortality framework to the Emicizumab Global Safety Database","volume":"19","author":"Peyvandi F","year":"2020","unstructured":"Peyvandi F, Mahlangu J, Pipe S Application of a hemophilia mortality framework to the Emicizumab Global Safety Database. J. Thromb. Haemost. 19(S1), 32\u201341 (2020).","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"e_1_3_6_29_2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1062860606288774","article-title":"Challenges of using medical insurance claims data for utilization analysis","volume":"21","author":"Tyree PT","year":"2006","unstructured":"Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am. J. Med. Qual. 21(4), 269\u2013275 (2006).","journal-title":"Am. J. Med. Qual."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2021-0278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T13:09:47Z","timestamp":1679231387000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2021-0278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.2217\/cer-2021-0278"],"URL":"https:\/\/doi.org\/10.2217\/cer-2021-0278","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}